Illumina Stock News

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. (Tuesday Market Open) Equity index futures are pointing higher as investors hope to build on Mondays rebound. Monday was a wild day with the stock market living up to its roller coaster reputation. However, with Federal Reserve Chairman Jerome Powell meeting with the Senate today, investors could still be a bit skittish. Stocks sold off on the open, with the S&P 500 (SPX) dropping 1.85% in the first hour but rallied off intraday lows to trim much of its losses. The S&P 500 closed down just 0.14%. The Nasdaq Composite ((COMP:GIDS)) led the selloff, falling 2.5% in the first hour of trading and easily broke the 14,900 support level. The next level of support would be around October 2021 lows near 14,200. However, the bulls refused to concede the line and pushed back to allow the Nasdaq to close 0.05% higher on a crazy day of trading. After spiking up over 23, the VIX ( Cboe Market Volatility Index ) subsided back below 21 as stocks rallied off their mid-day lows and closed at 19.33.

Illumina (ILMN) is trading ~4.6% higher in the pre-market after its preliminary revenue for 2021 and 2022 guidance exceeded the consensus on Monday. Many analysts have welcomed the

A nice bounce was overdue.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid Tumors BioA

The stocks making the biggest moves in premarket trading include Illumina, Rivian, Juniper Networks, and more.

Fourth-quarter 2021 results hit a "record," and Illumina's gearing up to report a big beat in 2022.

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones dipped more than 160 points in the previous session. Investors are awaiting earnings results from TD SYN

At the J.P. Morgan Healthcare Conference, Illumina Inc (NASDAQ: ILMN) said it expects about $4.517 billion, +39% Y/Y in 2021 revenue after the company logged the highest number of international pr

Illumina, Inc. (ILMN) JPMorgan 40th Annual Healthcare Conference (Transcript)

At J.P. Morgan Annual Healthcare Conference, Illumina reported Q4 preliminary revenue of ~$1.19B (consensus: $1.10B).For FY22, non-GAAP EPS is estimated to be in the range of

Illumina CEO Francis deSouza joins CNBC's Meg Tirrell to discuss his company's role in sequencing Covid and trading the virus' origins. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, T

Illumina's (ILMN) collaboration with SomaLogic will boost the fast-growing high throughput sector of the proteomics market to aid research in biology and disease.

On CNBCs "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ: ILMN ) has got "unbelievable

On CNBCs "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ: ILMN ) has got "unbelievable technology" and he also loves the companys diagnostic business. He recommended buying the stock. Cramer said Atai Life Sciences N.V. (NASDAQ: ATAI ) is "down so low that''s it''s now just a terrific spec." He recommended not to sell the stock down here. Cramer added Full story available on Benzinga.com